Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,319 across all filing types
Latest filing 2024-10-09 Regulatory Filings
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
PRTC's IPF Patient Research & Ph 2b On Track YE24
Regulatory Filings Classification · 98% confidence The document is a press release distributed via RNS (RNS Number: 4612H) announcing that PureTech Health PLC presented research findings related to its drug LYT-100 at the CHEST 2024 Annual Meeting. It details clinical trial updates (Phase 2b ELEVATE IPF) and patient survey results. This type of announcement, which communicates operational and clinical progress via a regulatory news service, fits best under the general 'Regulatory Filings' category (RNS) as it is not a formal financial report (like 10-K or IR), a specific management disclosure (like MANG or DIRS), or a dedicated earnings release (ER). Since it is a general corporate update distributed through the RNS system, RNS is the most appropriate classification.
2024-10-09 English
PRTC to Give 3 Presentations at CHEST 2024 Meeting
Regulatory Filings Classification · 99% confidence The document is a press release issued via RNS (RNS Number: 3440G) on October 1, 2024. It announces that PureTech Health PLC will be presenting data related to its drug candidate LYT-100 at the CHEST 2024 Annual Meeting. This is an announcement about company activities, specifically scientific presentations and clinical trial updates (Phase 2b data expected by year-end). It is not a full financial report (10-K or IR), an earnings release (ER), or a formal proxy/voting document. Since it is a general corporate announcement distributed through the regulatory news service (RNS), and it doesn't fit the specific categories like DIRS, DIV, or CAP, the most appropriate classification is the general regulatory announcement category, RNS, as it is a standard regulatory news service filing.
2024-10-01 English
6-K
Regulatory Filings
2024-09-27 English
KarXT/Cobenfy Approved by FDA; PRTC Receives $29M
Regulatory Filings Classification · 100% confidence The document is a press release issued by PureTech Health PLC on September 27, 2024, announcing that the FDA has approved KarXT (Cobenfy) for schizophrenia. The text details financial milestones triggered by this approval ($29 million) and mentions future royalty potential. It also discusses the company's R&D pipeline (LYT-100, LYT-200) and includes Important Safety Information (ISI) typical of drug approvals. This content strongly aligns with an Earnings Release (ER) or a general announcement of significant corporate/product news. Since it focuses on the immediate financial impact and key event (FDA approval) rather than being a comprehensive quarterly/annual report (10-K or IR), 'ER' (Earnings Release) is the most appropriate fit, as these announcements often coincide with or immediately follow financial reporting periods, even if the primary focus is regulatory news. Given the structure and content, it is a primary announcement of results/developments, fitting the ER definition better than the general 'RNS' fallback.
2024-09-27 English
Regulatory Filings 2024
Regulatory Filings
2024-09-18 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and explicitly states the reason for notification is 'An acquisition or disposal of voting rights'. It details the resulting situation where a shareholder (Citigroup Global Markets Limited) crossed a threshold, holding 5.053310% of voting rights. This type of mandatory disclosure regarding changes in significant share ownership thresholds directly corresponds to the Major Shareholding Notification category.
2024-09-06 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.